Copaxone Deemed Safe for Pregnancy in Updated Teva Guidelines

Teva has updated the prescribing information for Copaxone (glatiramer acetate), providing clearer guidance on its use during pregnancy. The changes follow years of global pharmacovigilance data, which found no safety concerns for pregnant women or newborns when the medication was used as prescribed.

The update also introduces the concept of 'bridging'—continuing treatment until conception—to prevent gaps in therapy for women with multiple sclerosis (MS).

The revised guidance is based on extensive real-world data. A 2016 analysis of pregnancies where Copaxone was used in the first trimester showed no increase in birth defects, preterm deliveries, or caesarean sections compared to the general population. Another study, covering 618 pregnancies from 1997 to 2020, similarly found no safety risks linked to the drug.

Global pharmacovigilance reports, involving 2,455 pregnancies with known outcomes, reinforced these findings. No evidence suggested higher risks of fetal or neonatal toxicity. The data also confirmed that Copaxone could be safely administered while breastfeeding, allowing women to maintain treatment without interruption.

For those with high disease activity, the updated information advises continuing Copaxone after a risk-benefit assessment. However, no long-term effects on MS progression in such cases have been documented in available sources. The exact number of women who began treatment during pregnancy remains undocumented.

The new 'bridging' option lets women stay on Copaxone until conception, reducing the chance of therapy interruptions. This approach aims to support better disease management before and during pregnancy.

The updated prescribing information reflects over a decade of clinical experience with Copaxone in pregnancy. Over 1,000 recorded outcomes show no increased risks to fetal development or neonatal health. Women with MS now have clearer options for managing their condition before, during, and after pregnancy.